HOUSE 1613118th CongressReferred to the Subcommittee on Health.
Drug Price Transparency in Medicaid Act of 2023
- Last Action
- 3/24/2023
Actions
- 2023-03-24Referred to the Subcommittee on Health.
- 2023-03-17Referred to the House Committee on Energy and Commerce.
- 2023-03-17Introduced in House
- 2023-03-17Introduced in House
CRS Summary
As of 2023-03-17 (00)
Drug Price Transparency in Medicaid Act of 2023
This bill requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with pharmacy benefit managers under Medicaid. The bill also extends funding for retail pharmacy surveys and requires additional information with respect to price concessions and survey participation to be made publicly available.
Cosponsors (20)
- Vicente Gonzalez (D-TX)
- Elise Stefanik (R-NY)
- Deborah Ross (D-NC)
- Rick Allen (R-GA)
- Jake Auchincloss (D-MA)
- Cory Mills (R-FL)
- Raja Krishnamoorthi (D-IL)
- David Trone (D-MD)
- Roger Williams (R-TX)
- Nicole Malliotakis (R-NY)
- Diana Harshbarger (R-TN)
- Nicholas Langworthy (R-NY)
- Scott Peters (D-CA)
- Mariannette Miller-Meeks (R-IA)
- Mark Alford (R-MO)
- Andy Harris (R-MD)
- Rashida Tlaib (D-MI)
- Glenn Thompson (R-PA)
- SANFORD BISHOP (D-GA)
- Don Bacon (R-NE)
Subjects
- Business records
- Congressional oversight
- Government information and archives
- Health care costs and insurance
- Home and outpatient care
- Inflation and prices
- Medicaid
- Prescription drugs
- Public contracts and procurement
- Retail and wholesale trades
- State and local government operations
- User charges and fees
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.